Every material Form 8-K MUSTANG BIO, INC. filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
At its December 22, 2025 annual meeting, Mustang Bio stockholders approved all four proposals, including electing seven directors, ratifying KPMG LLP as auditor, and increasing shares under its employee stock purchase plan and 2016 Incentive Plan. Separately, the company disclosed a December 17, 2025 agreement to terminate its CD20 license with Fred Hutch Cancer Center, under which the company will pay $730,000 to extinguish about $1.4 million in payables owed to Fred Hutch.
The 2016 Incentive Plan amendment adds 2,500,000 shares, and the 2019 ESPP amendment adds 250,000 shares.
The Incentive Plan amendment received 7,664,161 votes for, 198,991 against and 4,278 abstentions.
Each of the seven director nominees received at least 7,712,919 votes for.
Under the termination agreement, Fred Hutch would pay at least 10% of consideration from any third-party CD20 license granted within three years.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MUSTANG BIO, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →